IgA Nephropathy Biomarkers Evaluation Study (INTEREST)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-11-30

Study Completion Date

2027-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective cohort study is designed to examine the association between blood and urine biomarkers (including genetic variants) and long-term kidney disease progression among 2000 Chinese IgA nephropathy patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data

NCT01502579

IgA Nephropathy

COMPLETED

IgA Nephropathy Registration Initiative of High Quality (INSIGHT)

NCT03001947

IgA Nephropathy

RECRUITING

Correlation of Microbiome and Metabonomics With IgA Nephropathy

NCT05190848

IgA Nephropathy

RECRUITING

The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA)

NCT04858724

IgA Nephropathy

RECRUITING

Biomarkers for the Progression of IgA Nephropathy

NCT02529722

IgA Nephropathy Glomerular Diseases

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Glomerulonephritis is the leading cause of end-stage renal disease (ESRD) in China, where IgA nephropathy (IgAN) is the most common primary glomerulonephritis among individuals undergoing renal biopsy. The outcomes of IgAN vary highly among individuals; some have the stable renal function for lifetime and some quickly progress to ESRD. No biomarker is widely applied to predict the outcomes in IgAN yet. Previous GWAS studies including ours have identified some susceptibility loci associated with the development and clinical features of IgAN. In addition, a few cohort studies have revealed several genetic loci related to the progression of IgAN. But, all of the reported GWAS studies were based on a case-control design, which may not provide the information about the effect of genetic variants on the progression of disease. Previous cohort studies which focused on certain specific candidate genes cannot unbiasedly explore the progression related susceptibility loci. Furthermore, there is no study that integrates the information from whole genomic loci and serum and urine biomarkers to predict the long-term progression in IgAN. Therefore, we design a relative large prospective cohort study to examine the association between blood and urine biomarkers (including whole genomic loci) and long-term kidney disease progression among 2000 Chinese IgAN patients with relatively normal kidney function (eGFR≥60 ml/min/1.73 m2).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

IgA Nephropathy Glomerular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IgA nephropathy group

Eligible biopsy-proven primary IgA nephropathy patients.

No intervention

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female individuals aged 14 years or older
* Patients with biopsy-proven primary IgA nephropathy
* A renal biopsy available for reviewing must include 10 or more glomeruli.
* The first renal biopsy was performed within 3 years.
* eGFR ≥ 60 ml/min/1.73 m2 (MDRD formula);
* Individuals or their legal representative who are able to understand and have voluntarily signed the informed consent form (ICF).

Exclusion Criteria

* Relatives were diagnosed with biopsy-proven primary IgA nephropathy;
* Individuals had secondary IgA nephropathy due to diseases such as diabetes, chronic liver disease and systemic lupus erythematosus.

Minimum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No